382 related articles for article (PubMed ID: 19264882)
1. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration.
Rohrer B; Long Q; Coughlin B; Wilson RB; Huang Y; Qiao F; Tang PH; Kunchithapautham K; Gilkeson GS; Tomlinson S
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3056-64. PubMed ID: 19264882
[TBL] [Abstract][Full Text] [Related]
2. A targeted inhibitor of the complement alternative pathway reduces RPE injury and angiogenesis in models of age-related macular degeneration.
Rohrer B; Long Q; Coughlin B; Renner B; Huang Y; Kunchithapautham K; Ferreira VP; Pangburn MK; Gilkeson GS; Thurman JM; Tomlinson S; Holers VM
Adv Exp Med Biol; 2010; 703():137-49. PubMed ID: 20711712
[TBL] [Abstract][Full Text] [Related]
3. Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization.
Rohrer B; Coughlin B; Bandyopadhyay M; Holers VM
J Ocul Pharmacol Ther; 2012 Aug; 28(4):402-9. PubMed ID: 22309197
[TBL] [Abstract][Full Text] [Related]
4. Natural immunoglobulin M-based delivery of a complement alternative pathway inhibitor in mouse models of retinal degeneration.
Annamalai B; Parsons N; Nicholson C; Joseph K; Coughlin B; Yang X; Jones BW; Tomlinson S; Rohrer B
Exp Eye Res; 2021 Jun; 207():108583. PubMed ID: 33878326
[TBL] [Abstract][Full Text] [Related]
5. Regulatable Complement Inhibition of the Alternative Pathway Mitigates Wet Age-Related Macular Degeneration Pathology in a Mouse Model.
Parsons NB; Annamalai B; Rohrer B
Transl Vis Sci Technol; 2023 Jul; 12(7):17. PubMed ID: 37462980
[TBL] [Abstract][Full Text] [Related]
6. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury.
Huang Y; Qiao F; Atkinson C; Holers VM; Tomlinson S
J Immunol; 2008 Dec; 181(11):8068-76. PubMed ID: 19017999
[TBL] [Abstract][Full Text] [Related]
7. The use of Matrigel combined with encapsulated cell technology to deliver a complement inhibitor in a mouse model of choroidal neovascularization.
Annamalai B; Parsons N; Brandon C; Rohrer B
Mol Vis; 2020; 26():370-377. PubMed ID: 32476817
[TBL] [Abstract][Full Text] [Related]
8. Preliminary in vitro and in vivo assessment of a new targeted inhibitor for choroidal neovascularization in age-related macular degeneration.
Li W; Dong L; Ma M; Hu B; Lu Z; Liu X; Liu J; Li X
Drug Des Devel Ther; 2016; 10():3415-3423. PubMed ID: 27799741
[TBL] [Abstract][Full Text] [Related]
9. Delivery of CR2-fH Using AAV Vector Therapy as Treatment Strategy in the Mouse Model of Choroidal Neovascularization.
Schnabolk G; Parsons N; Obert E; Annamalai B; Nasarre C; Tomlinson S; Lewin AS; Rohrer B
Mol Ther Methods Clin Dev; 2018 Jun; 9():1-11. PubMed ID: 29234687
[TBL] [Abstract][Full Text] [Related]
10. A Targeted Inhibitor of the Alternative Complement Pathway Accelerates Recovery From Smoke-Induced Ocular Injury.
Woodell A; Jones BW; Williamson T; Schnabolk G; Tomlinson S; Atkinson C; Rohrer B
Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):1728-37. PubMed ID: 27064393
[TBL] [Abstract][Full Text] [Related]
11. Subretinal Rather Than Intravitreal Adeno-Associated Virus-Mediated Delivery of a Complement Alternative Pathway Inhibitor Is Effective in a Mouse Model of RPE Damage.
Annamalai B; Parsons N; Nicholson C; Obert E; Jones B; Rohrer B
Invest Ophthalmol Vis Sci; 2021 Apr; 62(4):11. PubMed ID: 33830174
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of FH Protection Against Neovascular AMD.
Borras C; Delaunay K; Slaoui Y; Abache T; Jorieux S; Naud MC; Sanharawi ME; Gelize E; Lassiaz P; An N; Kowalczuk L; Ayassami C; Moulin A; Behar-Cohen F; Mascarelli F; Dinet V
Front Immunol; 2020; 11():443. PubMed ID: 32318056
[TBL] [Abstract][Full Text] [Related]
13. Local production of the alternative pathway component factor B is sufficient to promote laser-induced choroidal neovascularization.
Schnabolk G; Coughlin B; Joseph K; Kunchithapautham K; Bandyopadhyay M; O'Quinn EC; Nowling T; Rohrer B
Invest Ophthalmol Vis Sci; 2015 Jan; 56(3):1850-63. PubMed ID: 25593023
[TBL] [Abstract][Full Text] [Related]
14. The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization.
Rohrer B; Coughlin B; Kunchithapautham K; Long Q; Tomlinson S; Takahashi K; Holers VM
Mol Immunol; 2011 Mar; 48(6-7):e1-8. PubMed ID: 21257205
[TBL] [Abstract][Full Text] [Related]
15. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice.
Banda NK; Levitt B; Glogowska MJ; Thurman JM; Takahashi K; Stahl GL; Tomlinson S; Arend WP; Holers VM
J Immunol; 2009 Nov; 183(9):5928-37. PubMed ID: 19828624
[TBL] [Abstract][Full Text] [Related]
16. Encapsulated Cell Technology-Based Delivery of a Complement Inhibitor Reduces Choroidal Neovascularization in a Mouse Model.
Annamalai B; Parsons N; Belhaj M; Brandon C; Potts J; Rohrer B
Transl Vis Sci Technol; 2018 Mar; 7(2):3. PubMed ID: 29576927
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the alternative complement pathway accelerates repair processes in the murine model of choroidal neovascularization.
Parsons N; Annamalai B; Obert E; Schnabolk G; Tomlinson S; Rohrer B
Mol Immunol; 2019 Apr; 108():8-12. PubMed ID: 30763805
[TBL] [Abstract][Full Text] [Related]
18. New Insights on Complement Inhibitor CD59 in Mouse Laser-Induced Choroidal Neovascularization: Mislocalization After Injury and Targeted Delivery for Protein Replacement.
Schnabolk G; Beon MK; Tomlinson S; Rohrer B
J Ocul Pharmacol Ther; 2017 Jun; 33(5):400-411. PubMed ID: 28333572
[TBL] [Abstract][Full Text] [Related]
19. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.
Sekine H; Kinser TT; Qiao F; Martinez E; Paulling E; Ruiz P; Gilkeson GS; Tomlinson S
Arthritis Rheum; 2011 Apr; 63(4):1076-85. PubMed ID: 21452327
[TBL] [Abstract][Full Text] [Related]
20. Excessive retinol intake exacerbates choroidal neovascularization through upregulated vascular endothelial growth factor in retinal pigment epithelium in mice.
Tan X; Takahashi H; Nishida J; Aoki A; Inoue T; Yanagi Y
Exp Eye Res; 2015 Feb; 131():77-83. PubMed ID: 25576666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
